Abstract:636 Background: Upper Tract Urothelial Carcinoma (UTUC) presents a challenging prognosis even after Radical Nephroureterectomy (RNU), and postoperative renal insufficiency further limits the options for adjuvant therapy. The efficacy of neoadjuvant chemotherapy for UTUC remains uncertain as past studies have not shown satisfactory results and have mostly been retrospective. There is an urgent need for a more promising regimen. This phase II study aims to investigate the efficacy and safety of a combination of chemotherapy (Gemcitabine/Cisplatin) and PD-1 inhibitor (Toripalimab) as neoadjuvant treatment (NT) in UTUC patients. Methods: We planned to enroll 34 UTUC patients with either cT1N0M0 (high grade) or cT2-3N0M0, confirmed by ureterorenoscopy biopsy and imaging. The treatment regimen included three or four cycles of NT (Gemcitabine, 800mg/m 2 , days 1 and 8/Cisplatin, 60mg/m 2 , day 1/Toripalimab, 240mg, day 1 of a 21-day cycle), followed by RNU and pelvic lymphadenectomy. The primary outcome was the pathological complete response (pCR) rate, with secondary outcomes including significant downstaging (≤pT1) rate, disease control rate (DCR), and safety. Results: To date, 17 patients have been accrued since August 1st, 2020, and recruitment is ongoing. Fifteen patients have completed treatments and were preliminarily analyzed, with two patients still undergoing treatment. The median age was 66.0 years, with 53.3% being male. The majority of patients had unifocal tumors, with a median maximum diameter of 2.8cm (0.4-5.8). All patients experienced obstructed hydronephrosis. Clinical T staging was confirmed by multi-parameter MRI, indicating two T2 and thirteen T3 patients. Ureterorenoscopy biopsy revealed 13 high-grade and two low-grade urothelial carcinoma patients. All patients were classified as high-risk UTUC. Twelve patients completed 4 cycles, and three underwent 3 cycles. The median interval time from initiation of NT to RNU and from the end of NT to RNU was 18.3 (11.4-22.7) weeks and 6.3 (0.1-11.6) weeks respectively. The pCR rate was 20.0% (3/15), the ≤pT1 rate was 53.3% (8/15), and the DCR was 100%. No grade 4-5 chemotherapy-related adverse events were recorded, but 26.7% (4/15) experienced grade 2 myelosuppression, 20% (3/15) grade 3, and 6.7% (1/15) grade 4. Two patients experienced immune-related adverse events after 4 cycles, including hypothyroidism (grade 2) and adrenal insufficiency (grade 2). No surgery-related complications or readmissions within one month were reported. With a median follow-up of 25.6 months, all patients remained alive and tumor-free. Conclusions: Preliminary analyses suggest that the combination of chemotherapy and a PD-1 inhibitor as NT exhibits promising pCR rate for UTUC. The treatment was manageable in terms of safety, with immune-related adverse events potentially leading to prolonged treatment periods. Clinical trial information: NCT04099589 .

Perioperative Chemotherapy on Survival in Patients With Upper Urinary Tract Urothelial Carcinoma Undergoing Nephroureterectomy: A Population-Based Study

Effect of Lymph Node Dissection on Stage-Specific Survival in Patients with Upper Urinary Tract Urothelial Carcinoma Treated with Nephroureterectomy

Impact of Nephron Sparing Surgery on Survival in Upper Urinary Tract Urothelial Carcinoma Patients Stratified by Tumor Characteristics

Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group

[Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function]

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

Prevalence, Clinicopathological Features, and Prognosis in Upper Tract Urinary Carcinoma Patients with Severe Preoperative Chronic Kidney Disease.

Survival and risk factors among upper tract urothelial carcinoma patients after radical nephroureterectomy in Northeast China

Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma

Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis

AB063. Comparisons of prognosis between urothelial carcinoma of the upper urinary tract and bladder with pT3-4 diseases

Role of lymph node dissection in the management of upper tract urothelial carcinomas: a meta-analysis

Comparisons Of Prognosis Between Urothelial Carcinoma Of The Upper Urinary Tract And Bladder With Pt3-4 Cancer

Prevalence and oncologic impact of chronic kidney disease for upper tract urothelial carcinoma in endemic area

Prognostic Nomogram for Overall Survival in Upper Urinary Tract Urothelial Carcinoma (UTUC) Patients Treated with Chemotherapy: a SEER-based Retrospective Cohort Study

Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.

Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis

Prognostic factors for overall survival in clinical node‐positive patients with upper tract urothelial carcinoma

The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma

Nephron-sparing Surgery Versus Radical Nephroureterectomy in the Treatment of Organ-localized Upper Urinary Tract Urothelial Carcinoma: A Population-based Study of 1581 Patients

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with high-risk UTUC.